Trial Profile
A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Oramed Pharmaceuticals
- 07 Mar 2023 Results assessing assess the safety and efficacy of multiple daily doses of oral insulin (ORMD-0801) in subjects with type 2 diabetes (T2DM) over 12 weeks published in the Diabetes, Obesity and Metabolism
- 29 Nov 2022 Results published in an Oramed Pharmaceuticals media release.
- 29 Nov 2022 According to an Oramed Pharmaceuticals media release, data from this study were published Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism.